US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Invivyd

< Previous 1 2 3 4 Next >
News headline image
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate at the Jefferies Global Healthcare Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Elects Two New Independent Members to its Board of Directors
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces CEO Transition
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
Tickers IVVD
News headline image
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Tickers IVVD
< Previous 1 2 3 4 Next >